The US Food and Drug Administration’s recent authorization of a second booster dose of Moderna, Inc.’s COVID-19 vaccine largely piggybacked on Israeli data specific to Pfizer Inc./BioNTech SE’s competing mRNA product.
“Safety and effectiveness of the Moderna COVID-19 vaccine second booster dose is inferred in large part by extrapolation from reported evidence following use of the Pfizer/BioNTech COVID-19 vaccine in individuals 60 years and older,” Center
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?